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Figure 1. Total bone marrow and weighted bone marrow 
dosimetry (presented are averages and 95% confidence 
intervals). 
 
Conclusion: With the use of the novel techniques such as p-
CSI and BM-HT quality of life impairing acute side effects 
such as cytopenias and dysphagia can be reduced. We 
propose WBME to better assess the impact on active bone 
marrow. 
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Purpose or Objective: Whole lung irradiation (WLI) of 12 to 
18 Gy is used as treatment for lung metastases in patients 
with Ewing sarcoma and Wilms tumour. This results in 
irradiation of normal tissues including heart and breast. 
Conventionally this treatment has been delivered with 
standard AP-PA fields. To minimise cardiac radiation dose 
and reduce the risk of subsequent late complications, we 
validated the use of VMAT to deliver WLI without increasing 
the predicted risks of secondary breast cancers compared to 
AP-PA fields. 
 
Material and Methods: Five female patient datasets (ages 
ranging from 3 to 18 years) were used for this retrospective 
study. The planning target volume (PTV) included total lung 
volume with a 1 cm margin (and adjacent vertebrae for three 
patients). Organs at risks included were heart, breast 
bud/tissue, liver and thyroid. 6 MV AP-PA (with segments) 
and RapidArc (2 or 3 full arcs) plans were created using the 
Eclipse treatment planning system (Version 11). Plans were 
calculated using the anisotropic analytical algorithm (AAA). 
The prescribed dose was either 15 Gy in 10 fractions or 18 Gy 
in 12 fractions based on the patient’s age. PTV D2%, D98% 
and D50% and mean and maximum doses for heart and breast 
were obtained. The absolute excess risk (AER) of cardiac 
mortality at 15 years post treatment was calculated for each 
plan based on an age-at-exposure adjusted relative risk per 
Gy obtained from published data (1,2,3,4) combined with 
contemporary UK population-based absolute risks. The risk of 
breast cancer induction was calculated using the model 
proposed by Schneider et al. (2011) (5). 
 
Results: The VMAT plans resulted in a similar minimum PTV 
coverage when compared to the AP-PA plans whilst reducing 
the PTV D2% by an average of 6.1% (4.1 – 9.1). The use of 
VMAT reduced the heart and breast mean dose by an average 
of 19.1% (11.7 – 30.5) and 16.2% (-2.2 – 30.4) respectively 
when compared to the AP-PA plans. The difference in AER of 
cardiac mortality at 15 years was lower for the VMAT plans by 
an average of 0.48% (0.11 – 0.98). The average excess 
absolute risk (EAR) for breast cancer induction across all 
plans decreased by 2.9% (-0.8 – 6.8) when compared to the 
conformal plans (assuming α/β = 3 Gy, α = 0.067 Gy-1, R = 
0.62, µ = 4.8/10000PY/Gy). 
 
 
Conclusion: VMAT achieved highly conformal plans and 
reduced cardiac late normal tissue complication probability 
whilst also reducing (or achieving similar) predicted risk of 
second cancer induction in breast tissue. 
 
PO-0862  
Comparison of Monte-Carlo computed 50 kV X-rays 
radiation therapy and EBRT for rectal cancer. 
M. Vidal
1Centre Antoine Lacassagne, Radiotherapy, Nice, France 
1, M. Gautier1, O. Croce2, J.P. Gerard1, K. Benezery1 
2Institute for Research on Cancer and Aging of Nice IRCAN, 
INSERM U1081 - CNRS UMR 7284 - UNS, Nice, France 
 
Purpose or Objective: Traditionally, patients with rectal 
cancer (T2 anterior low rectum, T3-T4 N0-N+) are treated 
with preoperative radiotherapy or chemoradiation (CAP 50 
regimen). 3D Conformal Radiation Therapy is conventionally 
delivered: 44 Gy more 6 Gy as a sequential boost to the high 
risk target volume (total dose 50 Gy). Another strategy would 
be to use the Contact Therapy technique [1] using 50 kV X-
rays (CXRT) to deliver higher dose (30 Gy) to the high risk 
target volume in addition to 44 Gy. The present study first 
describes CXRT dose computation with Monte-Carlo 
simulations and then compares the resulting dose 
(EBRT+CXRT) with the conventional treatment (EBRT only). 
 
Material and Methods: The CXRT machine Papillon 50™ 
installed in Centre Antoine Lacassagne (Nice, France) delivers 
a 50 kV X-ray beam with a dose rate close to 15 Gy/min, 
allowing treatment delivery more comfortable for the 
patients [2]. The system is currently used for treating skin 
and rectal cancers. The detailed geometry of the Papillon 
50™ machine [3] was fully generated in Monte-Carlo code 
PenEasy based on PENELOPE [4] and the resulting simulations 
were validated against measurements in water (depth dose 
curves and transverse dose profiles) for all applicators used 
for rectum cancer. For 10 patients with T2-T3 nodes smaller 
than 3 cm, dose distributions were calculated to irradiate the 
high risk target volume. For each patient, 30 Gy CXRT dose 
was computed with Monte-Carlo simulation in 3DCT patient 
data acquired in a position close to the rectal cancer CXRT 
position (genupectoral position). 6 Gy EBRT treatment was 
computed with the commercial TPS Isogray (Dosisoft) in the 
3DCT scan acquired in supine position. Both dose 
distributions were compared in terms of dosimetric indices 
computed for target volumes (conformity and homogeneity 
indices) and dose to organs at risk. 
 
Results: Monte-Carlo penEasy simulations are in good 
agreement with the Papillon50TM measurements in water for 
